---
schema_version: "secwatch.filing_event.v1"
accession: "0001829126-25-010101"
form_type: "8-K"
ticker: "NTHI"
cik: "0001979414"
company_name: "NEONC TECHNOLOGIES HOLDINGS, INC."
filed_at: "2025-12-17T23:59:59+00:00"
generated_at: "2026-05-16T12:57:39.963278+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# NeOnc reports updated NEO100 data: 24% radiographic remission, 44% PFS-6 in recurrent IDH1-mutant astrocytoma

## Summary
- 6 of 25 patients (24%) achieved radiographic remission vs <8% historical salvage therapies.
- 44% achieved 6-month progression-free survival (PFS-6), exceeding historical 21-31% benchmarks.
- 9 of 25 patients (36%) remain alive ≥18 months post NEO100 initiation; no significant toxicity seen.
- All patients had recurrent WHO Grade III/IV IDH1-mutant astrocytoma; data from Phase 1/2a and compassionate use.

## SEC filing metadata
- accession: 0001829126-25-010101
- form_type: 8-K
- ticker: NTHI
- cik: 0001979414
- company_name: NEONC TECHNOLOGIES HOLDINGS, INC.
- filed_at: 2025-12-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1979414/000182912625010101/0001829126-25-010101-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1979414/000182912625010101/neonctechnologies_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001829126-25-010101
- JSON: https://secwatch.observer/filing/0001829126-25-010101.json
- Plain text: https://secwatch.observer/filing/0001829126-25-010101.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.